CN Patent

CN114903904B — 瑞马唑仑药用盐和阿片样物质的注射用药物组合物

Assigned to Yichang Humanwell Pharmaceutical Co Ltd · Expires 2024-02-09 · 2y expired

What this patent protects

本发明提供了瑞马唑仑药用盐和阿片样物质的注射用药物组合物，所述药物组合物由包括瑞马唑仑药用盐、阿片样物质、甲氧基聚乙二醇‑聚(D,L‑乳酸)、冻干保护剂、pH调节剂以及注射用水制备而成。此外，还公开了该药物组合物的制备方法和用途。

USPTO Abstract

本发明提供了瑞马唑仑药用盐和阿片样物质的注射用药物组合物，所述药物组合物由包括瑞马唑仑药用盐、阿片样物质、甲氧基聚乙二醇‑聚(D,L‑乳酸)、冻干保护剂、pH调节剂以及注射用水制备而成。此外，还公开了该药物组合物的制备方法和用途。

Drugs covered by this patent

remimazolam-besylate (REMIMAZOLAM BESYLATE)

Patent Metadata

Patent number: CN114903904B
Jurisdiction: CN
Classification: —
Expires: 2024-02-09
Drug substance claim: No
Drug product claim: No
Assignee: Yichang Humanwell Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.